Shanghai Kehua Bio-Engineering Co.,Ltd (SHE:002022)

Market Cap	3.02B -4.7%
Revenue (ttm)	1.69B +2.6%
Net Income	-702.46M
EPS	-1.37
Shares Out	500.66M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,661,839
Open	6.05
Previous Close	6.04
Day's Range	5.95 - 6.09
52-Week Range	4.47 - 7.54
Beta	0.27
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About SHE:002022

Shanghai Kehua Bio-Engineering Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sale of reagents and instruments and services in China and internationally. The company offers immunoassay and clinical chemistry systems, HIV colloid gold test kits, ELISA HBV test kits, renal disease management solution, and automated comprehensive solutions for nucleic acid blood screening. It also provides automatic modular and clinical chemistry analyzers and clinical chemistry reagents test menu; automatic chemilum...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1981
• Employees: 1,870
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 002022

Financial Performance

In 2025, SHE:002022's revenue was 1.64 billion, a decrease of -6.63% compared to the previous year's 1.76 billion. Losses were -732.14 million, 14.3% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 29, 2026

Data Sources Report a data error